Head-to-Head Trial Compares Risankizumab and Vedolizumab in Treatment-Naive Ulcerative Colitis Patients
核心洞察
A new global clinical trial will directly compare the safety and efficacy of risankizumab versus vedolizumab in approximately 530 adults with moderate to severe ulcerative colitis (搜索) who are naive to targeted therapies.
The open-label study will randomize participants 1:1 across 285 worldwide sites, with risankizumab administered via IV induction followed by subcutaneous maintenance, while vedolizumab will be given intravenously throughout.
The trial duration spans approximately 69-71 weeks including screening and treatment periods, representing one of the first direct comparisons between these two approved UC therapies in treatment-naive patients.
A new global clinical trial is launching to directly compare two approved therapies for ulcerative colitis (搜索), potentially providing crucial guidance for clinicians treating patients with moderate to severe inflammatory bowel disease (搜索). The study will evaluate the safety and efficacy of risankizumab compared to vedolizumab in adult participants with moderate to severe ulcerative colitis who are naive to targeted therapies.
Study Design and Population
The open-label trial will enroll approximately 530 adult participants with moderate to severe UC who have not previously received targeted therapies. Participants will be randomized in a 1:1 ratio to receive either risankizumab or vedolizumab across 285 sites worldwide.
Ulcerative colitis (搜索) is a type of inflammatory bowel disease (搜索) that causes inflammation and bleeding from the lining of the rectum and colon. Both risankizumab and vedolizumab are approved medications for moderate to severe UC in multiple countries, making this head-to-head comparison particularly valuable for treatment decision-making.
Treatment Protocols and Administration
The study employs different administration strategies for each therapy. Participants randomized to risankizumab will receive intravenous administration during the induction period, followed by subcutaneous injection during the maintenance period. In contrast, participants assigned to vedolizumab will receive intravenous administration throughout the entire study duration.
Study Timeline and Monitoring
The trial duration varies slightly between treatment arms, lasting approximately 69 weeks for participants receiving risankizumab and 71 weeks for those receiving vedolizumab. This includes up to a 35-day screening period followed by treatment periods of 44 weeks for risankizumab and 46 weeks for vedolizumab.
Participants will attend regular outpatient visits during the study, with safety and efficacy monitored through medical assessments, evaluation of side effects, and completion of questionnaires. The study protocol acknowledges that participants may experience a higher treatment burden compared to their standard of care due to the intensive monitoring requirements.
Clinical Significance
This comparative effectiveness trial addresses an important clinical question by directly comparing two established therapies in treatment-naive patients with moderate to severe ulcerative colitis (搜索). The results could provide valuable evidence to guide treatment selection and optimize outcomes for patients beginning targeted therapy for inflammatory bowel disease (搜索).